Johnson & Johnson to Purchase Actelion for $30 Billion


Jan 26, 2017

Johnson & Johnson (J&J) has said that it is going to buy Swiss biotech Actelion Pharmaceuticals for $30 billion. The company also plans to spin out its research and development unit into a separate business. The deal is expected to close in mid-February.

The companies said in a statement that J&J will pay $280 per share for the Allschwil, Switzerland-based group, which is the Swiss franc equivalent of Sfr280.08 per share. Once the R&D unit is spun out, Actelion shareholders will receive a one-for-one holding in the new company as a dividend. According to the statement, the deal was unanimously approved by both boards, and no shareholder approval is required.

Johnson & Johnson CEO Alex Gorsky said: “We believe this transaction offers compelling value to both Johnson & Johnson and Actelion shareholders. Actelion has built an attractive, growing business with world-class commercial and clinical development capabilities.”

“Adding Actelion’s portfolio to our already strong Janssen Pharmaceuticals business is a unique opportunity for us to expand our portfolio with leading, differentiated in-market medicines and promising late-stage products. We expect to leverage our established global presence and commercial strength to accelerate growth and patient access to these important therapies. Further, we believe R&D NewCo will be strongly positioned to continue Actelion’s legacy of innovation and look forward to collaborating on the development of cutting-edge new therapies,” Gorsky added.


Johnson & Johnson to Purchase Actelion for $30 Billion last edit: 2017-02-01T16:37:46+00:00 da Luca

Leave a Reply

*The views and opinions expressed on IgeaHub belong to the authors only. They do not represent the views or opinions of any company or organization.

Follow Us

Join us

All rights reserved. Terms of use and Privacy Policy

Design by PT Webmaster

%d bloggers like this:
Skip to toolbar